N/A N=25 Feasibility of an Early Detection Program for Early Psychosis on a College Campus
Psychosis · First Episode Psychosis · Clinical High Risk for Psychosis
Primary: Duration of Untreated Psychosis
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Psychosis
Primary: Change From Baseline in Perceived Treatment Efficacy — 2.6; 1.6; 0.5; 0.5 score on a scale
N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
N/A N=39 Prevention and Early Identification for High Risk Youth in School-based Clinics
Community Mental Health Services · Adolescent Well Being · Resilience, Psychological
Primary: Kiddie Computerized Adaptive Testing Self Report (K-CAT-S) — 45.08; 39.45; 36.24; 41.3 Score on a scale — p=0.37
N/A N=77 Psychosis Screening in Juvenile Justice
Psychotic Disorders · Psychosis Nos/Other
Primary: Number of Participants Who Used Outpatient Mental Health Services — 20; 9 Participants — p=.053
N/A N=292 Early Detection and Intervention for the Prevention of Psychosis
Schizophrenia · Bipolar Disorder · Depression
Primary: Psychotic Symptoms — 9.2; 6.7 units on a scale — p=.0034
N/A N=50 Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
Attenuated Psychosis Syndrome
Primary: Brain Volume — 19.8; 54.8; -0.489; -6.28 Change in mm cubed (baseline -followup)
N/A N=85 Horyzons: Implementation in Clinical Practice
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorders
Primary: Mean Change in UCLA Loneliness Scale Score (Both Cohorts) — 42.96; 45.08; 41.95; 42.47 score on a scale
N/A N=51 Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2
Suicide · Psychosis
Primary: Calgary Depression Rating Scale (CDRS) — 18.20; 17.15; 16.09; 15.39 score on a scale
N/A N=60 mHealth for Psychosis Help-seeking
Psychosis
Primary: Change in Treatment Seeking Steps — 6.43; 10.08; 7.65; 9.58 score on a scale
N/A N=14 Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
Schizophrenia
Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)
N/A N=8 Clinical Interviews With Detainees With Early Psychosis
First-Episode Psychosis
Primary: Number of Referrals to Correctional Health Services (CHS) — 8 Participants
N/A N=5 Cognitive Behavioral Suicide Prevention for Psychosis: Aim 1
Suicide · Psychosis
Primary: Calgary Depression Rating Scale (CDRS) — 13.60; 9.00; 11.00; 7.60 score on a scale
Phase 1 N=11 Glutamate Reducing Interventions in Schizophrenia
Clinical High Risk for Psychosis
Primary: Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 — 0.40684405; -0.081559; 0.0219668; -0.0269017 Percent change
Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Phase 4 N=26 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01
N/A N=24 rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia
Schizophrenia
Primary: Change in Precuneus Functional Activation — 0.0329; 0.067; -0.010 Beta coefficient change (Target vs Foil) — p=0.32
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
Phase 1 N=127 NAPLS Omega-3 Fatty Acid Versus Placebo Study
Psychosis
Primary: Rate of Conversion to Psychosis. — 4; 3 Participants — p=.51
N/A N=45 Minnesota Community-Based Cognitive Training in Early Psychosis
Schizophrenia · Psychosis · Schizoaffective Disorder
Primary: Speed of Processing From the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 41.75; 41.2; 24.82…
N/A N=55 Feasibility Trial of a Single Session of Crisis Response Planning for Youth at High Risk for Suicide
Suicide Prevention
Primary: Number of Participants With Self-reported Use of the Treatment Plan in the Crisis Response Planning (CRP) Treatment Arms — 14; 8 Participants — p=.014
N/A N=120 Specialized Treatment Early in Psychosis (STEP)
Schizophrenia and Disorders With Psychotic Features
Primary: Number of Patients Hospitalized — 25; 14 participants — p=0.018
N/A N=38 Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy
Schizophreniform Disorders
Primary: Change Over Time on the mDES - Positive — 0.35; 0.42; 0.62; 0.25 units on a scale
N/A N=55 Improving Accessibility and Personalization of CR for Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Treatment Satisfaction — 5.25; 5.32 score on a scale
N/A N=13 Perceptual Retraining to Reduce Suicide Risk
Perceptual Olfactory Bias
Primary: Percent Change in Olfactory Perceptual Bias — 21.33; -5 Percent of correctly identified odors — p=.08
N/A N=30 A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
Psychotic Disorders · Schizophrenia · Schizoaffective Disorder
Primary: Change in Tablets Routine Questionnaire (TRQ, Past Week) From Screen to Week 25 Visit — 56.2 percentage of adherence — p=.012
N/A N=12 Facilitating Engagement in Evidence-Based Treatment for Early Psychosis
Psychotic Disorders
Primary: Change in Decisional Conflict Scale — 0.55 score on a scale — p=.95
Phase 4 N=198 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
Schizophrenia
Primary: Percentage of Participants That Responded to Treatment — 62.8; 56.8 percentage of response — p=.61